AUTHOR=Wang Qian , Yu Jianmin , Deng Weizhu , Liu Chao , Yang Jian , Li Yaqing , Cai Guangyan , Chen Xiangmei , Dong Zheyi 

TITLE=Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1372421

DOI=10.3389/fphar.2024.1372421

ISSN=1663-9812

ABSTRACT=<sec><title>Background</title><p>Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are associated with cardiovascular benefits. The aim of this systematic review and meta-analysis is to summarize the influence of SGLT2i on the incidence of acute kidney injury (AKI), and to ascertain whether it is affected by confounding variables such as age, baseline renal function and concurrent use of renin-angiotensin-aldosterone system inhibitors (RAASi) or mineralocorticoid receptor antagonists (MRA).</p></sec><sec><title>Methods</title><p>PubMed, Embase, and Cochrane Library databases were searched for randomized controlled trials comparing the influence of SGLT2i versus placebo/blank treatment on AKI in the adult population. A fixed-effect model was used if the heterogeneity was not significant; otherwise, a randomized-effect model was used.</p></sec><sec><title>Results</title><p>Eighteen studies comprising 98,989 patients were included. Compared with placebo/blank treatment, treatment with SGLT2i significantly reduced the risk of AKI (risk ratio [RR]: 0.78, 95% confidence interval [CI]: 0.71 to 0.84, <italic>p</italic> &lt; 0.001; <italic>I</italic><sup>2</sup> = 0%). Subgroup analysis suggested consistent results in patients with diabetes, chronic kidney disease, and heart failure (for subgroup difference, <italic>p</italic> = 0.32). Finally, univariate meta-regression suggested that the influence of SGLT2i on the risk of AKI was not significantly modified by variables such as age (coefficient: 0.011, <italic>p</italic> = 0.39), baseline estimated glomerular filtration rate (coefficient: −0.0042, <italic>p</italic> = 0.13) or concomitant use of RAASi (coefficient: 0.0041, <italic>p</italic> = 0.49) or MRA (coefficient: −0.0020, <italic>p</italic> = 0.34).</p></sec><sec><title>Conclusion</title><p>SGLT2i may be effective in reducing the risk of AKI, and the effect might not be modified by age, baseline renal function and concurrent use of RAASi or MRA.</p></sec>